Pancryos strikes deal with Brigham and Women’s Hospital on type 1 diabetes drug

The Copenhagen-based firm has entered a global license agreement with Brigham and Women’s Hospital regarding an encapsulation device for the delivery of a stem-cell derived treatment for type 1 diabetes.

Jacqueline Ameri, CEO of Pancryos | Photo: Bioinnovation Institute / PR

Pancryos, which is based out of Copenhagen, Denmark, is working on a stem-cell based treatment for type 1 diabetes dubbed Paninsula, and has now signed an exclusive license deal with the US-based Brigham and Women’s Hospital (BWH), the firm reports in a press release.

The two parties have decided that the delivery mechanism of the drug will be encapsulation device Cemed, which was developed by BWH in collaboration with Harvard University and the University of Massachusetts Medical School.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs